Loading...
•
Dec 31, 2025
OrthoPediatrics Q4 2025 Earnings Report
OrthoPediatrics Q4 2025 Earnings Report
Key Takeaways
OrthoPediatrics delivered a strong fourth quarter with revenue growing 17% year-over-year to $61.6 million, driven by robust performance in the Scoliosis and Trauma & Deformity segments. While the company reported a net loss of $10.1 million, it achieved positive Adjusted EBITDA of $4.8 million for the quarter and provided a positive outlook for 2026, targeting free cash flow breakeven.
Q4 2025 revenue increased 17% to $61.6 million compared to $52.7 million in Q4 2024.
The Scoliosis segment showed significant growth, with Q4 revenue rising to $17.6 million from $15.6 million in the prior year.
Adjusted EBITDA for the fourth quarter improved to $4.8 million, up from $3.0 million in Q4 2024.
The company ended the year with a strong balance sheet, including $62.9 million in cash and short-term investments.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
For the full year 2026, OrthoPediatrics expects revenue between $262 million and $266 million, representing 11% to 13% growth, and aims to reach free cash flow breakeven.
Positive Outlook
- Anticipated revenue growth of 11% to 13% for FY 2026.
- Targeting approximately $25.0 million in Adjusted EBITDA.
- Expectation to achieve breakeven Free Cash Flow in 2026.
- Planned deployment of approximately $10.0 million in new instrument sets.
- Aggressive market-based clinic expansion strategy for the OPSB division.
Challenges Ahead
- Revenue growth rate of 11-13% is a deceleration from the 15% growth seen in 2025.
- Continued reliance on seasonal summer and holiday peaks for performance.
- Ongoing impact of European Union Medical Device Regulation fees.
- Exposure to potential minimum purchase commitment costs.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...